CVS Health Preannounces Large Earnings Miss, But Analysts Stay Bullish On Long-Term Recovery
CVS Health Preannounces Large Earnings Miss, But Analysts Stay Bullish On Long-Term Recovery
Analyst Jessica Tassan maintained an Overweight rating and price target of $72.Shares of CVS Health Corp (NYSE:CVS) were under pressure in early Monday trading after the company preannounced an earnings miss for the third quarter.
CVS Health Corp（纽交所：CVS）股价在周一早盘交易中承受压力，因公司提前发布了第三季度盈利未达预期的消息。
The company reported its results amid an exciting earnings season. Here are some key analyst takeaways.
该公司在备受关注的盈利季节中报告了其业绩。以下是一些关键分析师的看法。
Piper Sandler On CVS Health
派杰投资对西维斯健康的看法
Analyst Jessica Tassan maintained an Overweight rating and price target of $72.
分析师Jessica Tassan维持“增持”评级，并设定价格目标为72美元。
CVS Health preannounced a significant MLR (medical loss ratio) and earnings miss for the third quarter and withdrew its full-year guidance, Tassan said in a note. "During 3Q24, CVS recorded $1.1B of premium deficiency reserves primarily related to the Medicare and Individual Exchange businesses within HCB (health care benefits)," she wrote.
Tassan在一份消息中表示，西维斯健康提前发布了第三季度的重大医疗损失比率（MLR）和盈利未达预期的消息，并撤销了全年预测指引。“她写道：“在2024年第三季度，西维斯健康录得11亿美元的保险费不足准备金，主要与医疗保险和个体交换业务相关，属于医疗保健福利板块。”
While rates, risk adjustment and the IRA are exerting pressure on Medicare Advantage, CVS Health has some "self-induced" issues in the Healthcare Benefits (HCB) segment, which should begin to resolve in 2025, the analyst stated. David Joyner has taken over CEO, effective immediately, and could deliver a "multi-year earnings recovery," she added.
尽管医疗保险利率、风险调整和IRA给医疗保险优势带来了压力，但西维斯健康在医疗保健福利板块中也有一些“自身造成”的问题，这些问题应该在2025年开始得到解决，分析师指出。她补充说，David Joyner已立即接任CEO，可能提供“跨年度的盈利恢复”
Check out other analyst stock ratings.
查看其他分析师的股票评级。
Truist Securities On CVS Health
Truist Securities对西维斯健康的看法
Analyst David MacDonald reiterated a Buy rating and price target of $76.
分析师大卫·麦克唐纳重申买入评级，并设定目标价格为76美元。
CVS Health preannounced its third-quarter adjusted earnings at $1.05-$1.10 per share, significantly below consensus of $1.69 per share, MacDonald said. The results include a charge of around $1.1 billion to record premium deficiency reserves primarily related to the Medicare and Individual Exchange books, which translates to an adjusted earnings headwind of 63 cents per share, he added.
西维斯健康提前公布了第三季度调整后的每股收益为1.05美元至1.10美元，大幅低于1.69美元的共识，麦克唐纳表示。这些结果包括约11亿美元的费用，用于记录主要与医疗保健和个人交易所账目相关的保险金不足准备金，这导致每股调整后的收益受到63美分的不利影响，他补充说。
Management no longer believes its prior guidance for 2024 is appropriate, "given continued elevated utilization pressure," the analyst stated. CEO Karen Lynch stepped down and was replaced by industry veteran Joyner, who brings "a wealth of experience in pharmacy services," he further wrote.
管理层不再认为其2024年的先前指引是恰当的，"鉴于持续增加的利用压力，"该分析师表示。首席执行官卡伦·林奇辞职，并由行业资深人士乔纳接替，后者在药房服务领域拥有"丰富的经验，"他进一步写道。
CVS Price Action: Shares of CVS Health were down 1.17% to $58.98 at the time of publication on Monday.
西维斯健康股价表现：周一发布时，西维斯健康的股价下跌1.17%，至58.98美元。
- NIO, ASML, And CVS Health Are Among Top 10 Large Cap Losers Last Week (Oct 14-18): Are The Others In Your Portfolio?
- NIO、ASML 和西维斯健康是上周（10月14日至18日）大盘中十大跌幅最大的股票之一：您的投资组合中还有其他股票吗？
Photo via Wikimedia Commons
照片通过Wikimedia Commons
